Pelthos Therapeutics Inc. Annual Report - How They Did This Year

Hey there, fellow investor! Let's look at Pelthos Therapeutics Inc.'s past year. This will help you understand the company better and decide if it fits your portfolio.

Big Picture: What Happened This Year?

The past year (ending December 31, 2025) was busy for Pelthos! They made big moves to grow their business. They expanded their dermatology product line and secured a lot of funding. Pelthos is growing fast. They want a bigger market share with new and acquired products.

Major Business Moves and Financial Activities

• Going Public (IPO): A huge milestone! Pelthos had its IPO in February 2024. This made them a public company. They sold new shares to big investors and regular people like us. This move gave them a lot more money. It also made them more visible in the drug industry and financial world. This money will fund future growth and purchases.
• Growing Through Acquisitions: Pelthos expanded its product line and technology. They focused especially on skin treatments. They bought several key companies:
  • They bought the Xepi assets from Biofrontera Inc. and Ferrer. Xepi (ozenoxacin) treats impetigo, a common skin infection. This immediately added a product already being sold. It brings in money right away.
  • They also bought the XEGLYZE assets. XEGLYZE (tirbanibulin) treats actinic keratosis on the face or scalp. This added more skin treatments. It's another product already being sold.
  • They also bought LNHC Inc., which gave them rights to new technology and the Sato License. These purchases strengthen a company's patents and ideas, potentially adding early-stage drugs or core technologies that could lead to new products and revenue later. Together, these buys show Pelthos wants new patents, ideas, and products, aiming to grow the company.
• Securing Funding: Pelthos needed money to pay for these purchases, current research, and day-to-day business. So, they were busy getting funds:
  • They took several bridge loans in 2024 and 2025. These came from various parties, including Ligand. Bridge loans are short-term, high-interest loans. They cover funding gaps until Pelthos gets bigger, more stable funding. This could be selling more stock or a larger loan. These loans show a constant need for money during this growth period.
  • Pelthos also sold a senior unsecured convertible note in July 2024. They sold more convertible notes in November 2025. Convertible notes are loans. They can change into company shares at a set price or when certain things happen. They give money right away without immediately issuing more shares. But they risk more shares issued later, reducing your ownership percentage if converted. "Senior unsecured" means they get paid back before regular shareholders if the company closes. They are not secured by specific assets.
  • Looking ahead, Pelthos got a venture loan and security agreement in January 2026. This kind of loan is common for growing companies. It's especially used in biotech and health industries. Special loan providers typically give venture loans. They are often backed by the company's patents, ideas, and other assets. They give money without immediately issuing more shares. But they come with certain rules and interest payments.
• Key Licenses and Royalties: Pelthos has license and royalty agreements for products like ZELSUVMI, Xepi, and the Sato License. Partners include Ligand, UNC, Nomis, and NRV Ligand Madison. These deals are key to how a drug company makes money. They usually include upfront payments. They also pay when certain development or sales targets are hit. Plus, there are regular payments based on a percentage of sales. This is how Pelthos earns money from its patents, ideas, and product sales. They use partnerships to reach more customers or pay for development.

Potential Risks to Keep in Mind

• Customer Concentration: Pelthos said most of its business comes from three main customers. This is a big reliance. If one or more of these customers cut orders, delayed payments, or switched, it would hurt Pelthos a lot. Sales, money flow, and overall financial well-being would suffer. This risk is especially high for companies with few products or a small, specialized market.
• Operational Challenges: There was talk about "out-of-specification issues related to API." API is the active part of a drug. "Out-of-specification" means the API didn't meet set quality rules. This suggests problems with quality control, manufacturing, or supply. Such issues are very serious for a drug company. They can cause manufacturing delays, product recalls, not following rules, and higher costs. This ultimately hurts product availability, reputation, and sales.
• Complex Financing: Pelthos uses complicated ways to get money, like convertible notes and bridge loans. These provide needed money. But they can be tricky for investors to understand. Convertible notes, especially, risk more shares issued later, reducing your ownership percentage if converted. This is true if the stock price rises. The rules of these loans (like interest rates or conversion prices) can also affect the company's ability to manage money and how much the stock is worth.
• Contingent Payments for Acquisitions: Some purchases involve future payments. These depend on hitting certain sales goals or targets. So, the full cost isn't fixed. It depends on how well the bought products do. This setup can make the seller and buyer want the same success. But it creates financial risk for Pelthos. These potential future payments could become big if the products do well.

Is Pelthos a Good Investment?

Based on this, Pelthos is clearly in a period of growth. They are actively buying new things and getting money. The IPO was a major step. The purchases suggest a strong push to expand their product line and market share, especially in dermatology with products already being sold, like Xepi and XEGLYZE. The reliance on a few customers and possible problems with drug ingredient quality are key things to watch. These are big business risks.

To make an informed decision, consider reviewing their full 10-K report for detailed financial results, including revenue, profit, and cash flow. Also, understanding the market size and competitive landscape for their acquired products will be helpful.